The notice of allowance is the US Patent and Trademark Office’s (USPTO’s) official communication that the examination of the patent application has been successfully completed and that a
The use of a vitamin A analog called 4-HPR, or fenretinide, in combination with certain other drugs, or ‘partnering agents’, is reportedly showing promise for selectively killing certain
Nagarkatti joined the company in 1976 and held roles in R&D, production, operations and sales before being elected president and chief operating officer in 2004. Toan is the
Adar Palis, vice president and CIO of Harrison Medical Center, said the organization spent more than two years evaluating technology from several vendors before selecting GE Healthcare, largely
Regional Anesthesia (RA) sales of the company’s flagship ON-Q product lines increased by 9% for first quarter of 2009, to $24.7 million compared to $22.6 million with first
Fiscal 2009 Outlook Saxelby concluded, “I am very pleased with the progress we’ve made in the first half of fiscal 2009. Landauer’s performance demonstrates the success of our
Business Outlook For the second quarter of 2009, the company expects earnings per share to range between $0.23 and $0.25 and revenue to range from $620 million to
ProCure Treatment Centers, a provider of proton therapy solutions, and Ion Beam Applications or IBA, a provider of cancer diagnosis and therapy solutions, have reported that IBA has
Gen-Probe has reported that it plans to initiate a pivotal clinical study of its investigational PCA3 assay that could lead to regulatory approval by the FDA. Gen-Probe’s clinical
US-based Cougar Biotechnology has initiated a Phase III clinical trial of its lead drug candidate CB7630 in patients with chemotherapy-naive castration-resistant prostate cancer. The Phase III trial is
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.